STOCK TITAN

Avadel Pharmaceuticals plc Ordinary Share - AVDL STOCK NEWS

Welcome to our dedicated page for Avadel Pharmaceuticals plc Ordinary Share news (Ticker: AVDL), a resource for investors and traders seeking the latest updates and insights on Avadel Pharmaceuticals plc Ordinary Share stock.

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a specialty pharmaceutical company headquartered in Dublin, Ireland, with operations in St. Louis, Missouri, and Lyon, France. The company focuses on developing, identifying, and commercializing differentiated pharmaceutical products designed to be safe, effective, and easy to administer, thereby improving patient adherence and outcomes. Avadel's products primarily target the urology, central nervous system (CNS) / sleep, and hospital markets.

One of Avadel's flagship products is LUMRYZ™, an extended-release formulation of sodium oxybate, approved by the U.S. Food & Drug Administration (FDA) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. LUMRYZ is notable for its once-at-bedtime dosing, which eliminates the need for a middle-of-the-night dose, making it more convenient for patients.

The FDA granted LUMRYZ seven years of Orphan Drug Exclusivity, recognizing it as a major contribution to patient care over existing therapies. The approval was supported by results from the REST-ON trial, a Phase 3 study that demonstrated significant improvements in EDS, the Clinician Global Impression of Improvement (CGI-I), and reduced the frequency of cataplexy attacks.

Avadel recently announced its financial results for the third quarter ended September 30, 2023, reporting $7.0 million in net product revenue from LUMRYZ sales. The company has seen robust demand and positive feedback from the narcolepsy community, healthcare providers, and payers. Notably, CVS Health has moved LUMRYZ to preferred status starting January 1, 2024. Avadel also filed a supplemental NDA to extend LUMRYZ's indication to pediatric patients with narcolepsy, further expanding its market reach.

Financially, Avadel reported a net loss of $36.3 million for the quarter, driven by higher selling, general, and administrative expenses related to the LUMRYZ launch. Despite these challenges, the company maintains a strong cash position of $153.2 million as of September 30, 2023.

Looking ahead, Avadel plans to issue its Annual Report on Form 10-K for the year ended December 31, 2023, on February 29, 2024. The company continues to focus on expanding its product pipeline, including initiating a Phase 3 trial for idiopathic hypersomnia and optimizing commercial execution for LUMRYZ.

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced interim results from its RESTORE study at the 2022 AAN Meeting. The study evaluated patient preferences regarding FT218, a once-nightly formulation of sodium oxybate for narcolepsy. Findings revealed 94.3% (33/35) of participants preferred FT218 over the twice-nightly dosing regimen. Additionally, nocturnal adverse events highlighted issues with the second dose, with 63% of participants missing it, causing worsened symptoms. FT218 has the potential to significantly ease the burden on narcolepsy patients if approved.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.02%
Tags
none
-
Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced positive secondary endpoint results from its Phase 3 REST-ON trial of FT218, an investigational sodium oxybate formulation for narcolepsy. Published in CNS Drugs, the data demonstrate FT218's ability to improve nighttime sleep disruptions significantly compared to placebo. Key findings show FT218 led to fewer nocturnal arousals and improved sleep quality across various doses. The trial supports FT218's potential as an effective treatment for excessive daytime sleepiness and cataplexy, with a marketing application currently under review by the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
-
Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced that CEO Greg Divis will participate in two upcoming investor conferences. The first is the Stifel 2022 Virtual CNS Day on March 29 at 12:00 p.m. E.T., followed by the 21st Annual Needham Virtual Healthcare Conference on April 11 at 2:15 p.m. E.T. Live webcasts and archived recordings will be accessible on Avadel's Investor Relations website for 90 days post-conference. Avadel focuses on innovative medications like FT218, aimed at treating narcolepsy symptoms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences
Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) provided a corporate update, emphasizing ongoing FDA review for FT218, a treatment for narcolepsy. Key highlights include multiple presentations at World Sleep 2022 showcasing FT218's effectiveness, and the extension of $117.4 million convertible notes maturity to October 2023. Additionally, net loss for Q4 2021 was $22.3 million, worsening from $11.3 million in Q4 2020. R&D expenses decreased to $2.1 million, while SG&A expenses surged to $21.0 million. The company remains focused on potential commercialization of FT218, pending FDA approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
-
Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced the appointment of Brandi Robinson as Senior Vice President of Corporate Affairs, aimed at strengthening its operational and commercial infrastructure. Robinson, with over 25 years of experience in the biopharmaceutical industry, will support the upcoming launch of FT218, designed to treat narcolepsy symptoms. The transition includes a grant of 215,000 stock options at an exercise price of $7.22 per share, aligning her interests with the company's goals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
management
-
Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) will host a conference call on March 17, 2022, at 8:30 a.m. ET to provide a corporate update and discuss financial results for Q4 and the full year ended December 31, 2021. Investors can join via phone or through a live webcast on Avadel’s website, which will be available for replay for 90 days. The company focuses on innovative medication solutions, particularly its investigational drug candidate FT218 aimed at treating narcolepsy-related excessive daytime sleepiness and cataplexy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.73%
Tags
Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced new findings at World Sleep 2022 regarding its lead drug candidate, FT218, an investigational formulation of sodium oxybate for narcolepsy. A discrete choice experiment revealed that patients and clinicians prefer once-nightly dosing over twice-nightly dosing for oxybate therapy. Post-hoc analyses from the Phase 3 REST-ON trial showed FT218 significantly improved daytime sleepiness and sleep quality. Interim data from the RESTORE trial indicated FT218 was generally well tolerated. The FDA is currently reviewing FT218's marketing application.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
-
Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced that CEO Greg Divis will participate in a virtual fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17 at 10:40 a.m. ET. The event will be accessible via a live webcast on Avadel's Investor Relations website, along with an archived recording available for 90 days post-conference. Avadel focuses on innovative medications, with its lead drug candidate FT218 aimed at treating narcolepsy-related symptoms using proprietary drug delivery technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
conferences
-
Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) will present eight posters at World Sleep 2022 from March 11-16 in Rome, Italy, showcasing new data from the Phase 3 REST-ON clinical trial of FT218 and the ongoing RESTORE study. FT218 is an investigational once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness (EDS) and cataplexy in narcolepsy patients, currently under FDA review. The company will also support a Satellite Symposium addressing patient needs in narcolepsy treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
conferences clinical trial
Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) has appointed Douglas Williamson as the new Chief Medical Officer. With over 25 years of experience in the biopharmaceutical industry, Williamson's expertise in R&D and clinical development, particularly in neuroscience, is expected to be instrumental in advancing the company's lead candidate, FT218, for narcolepsy treatment. In recognition of his hiring, the Compensation Committee granted him options to purchase 275,000 shares at $6.60 each, with a four-year vesting schedule. This strategic move is seen as pivotal for Avadel's growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
management

FAQ

What is the current stock price of Avadel Pharmaceuticals plc Ordinary Share (AVDL)?

The current stock price of Avadel Pharmaceuticals plc Ordinary Share (AVDL) is $10.31 as of December 20, 2024.

What is the market cap of Avadel Pharmaceuticals plc Ordinary Share (AVDL)?

The market cap of Avadel Pharmaceuticals plc Ordinary Share (AVDL) is approximately 980.5M.

What is Avadel Pharmaceuticals plc?

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a specialty pharmaceutical company focused on developing differentiated pharmaceutical products for urology, CNS/sleep, and hospital markets.

What is LUMRYZ?

LUMRYZ is an extended-release formulation of sodium oxybate, approved by the FDA for treating cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. It is taken once at bedtime.

Where is Avadel Pharmaceuticals headquartered?

Avadel Pharmaceuticals is headquartered in Dublin, Ireland, with additional operations in St. Louis, Missouri, and Lyon, France.

What recent financial results did Avadel report?

For the third quarter ended September 30, 2023, Avadel reported $7.0 million in net product revenue from LUMRYZ sales and a net loss of $36.3 million.

What distinguishes LUMRYZ from other treatments?

LUMRYZ is the first and only once-at-bedtime oxybate treatment for narcolepsy, offering a more convenient dosing regimen compared to twice-nightly oxybate products.

What are the most common side effects of LUMRYZ?

The most common side effects include nausea, dizziness, bedwetting, headache, and vomiting.

What is the significance of LUMRYZ's Orphan Drug Exclusivity?

The FDA granted LUMRYZ seven years of Orphan Drug Exclusivity due to its significant contribution to patient care, providing a once-nightly dosing alternative to existing treatments.

How did the narcolepsy community respond to the launch of LUMRYZ?

The launch received overwhelmingly positive feedback, with early patient demand and significant support from healthcare providers and payers.

What other areas does Avadel Pharmaceuticals focus on?

In addition to narcolepsy, Avadel focuses on developing treatments for urology and hospital markets.

What are Avadel’s future plans for LUMRYZ?

Avadel plans to expand LUMRYZ's indication to pediatric patients and continue its Phase 3 trials for idiopathic hypersomnia.

Avadel Pharmaceuticals plc Ordinary Share

Nasdaq:AVDL

AVDL Rankings

AVDL Stock Data

980.48M
91.76M
4.77%
80.29%
9.15%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
DUBLIN